Who are Lamotrigine novel formulation's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Generic lamotrigine, Lamotrigine tablet, Lamotrigine generic "B", lamotrigine (generic Teva), Brand lamotrigine, Lamictal TM.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lamotrigine-novel-formulation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Lamotrigine novel formulation — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lamotrigine novel formulation (Lamotrigine novel formulation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant / Antiepileptic agent. Area: Neurology.

phase 3 Anticonvulsant / Antiepileptic agent Voltage-gated sodium channels; glutamate release inhibition Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Lamotrigine novel formulation (Lamotrigine novel formulation) — University Hospitals Cleveland Medical Center. Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Lamotrigine novel formulation TARGET	Lamotrigine novel formulation	University Hospitals Cleveland Medical Center	phase 3	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels; glutamate release inhibition
Generic lamotrigine	Generic lamotrigine	University of Maryland, Baltimore	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
Lamotrigine tablet	Lamotrigine tablet	Dhaka Medical College	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
Lamotrigine generic "B"	Lamotrigine generic "B"	University of Cincinnati	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
lamotrigine (generic Teva)	lamotrigine (generic Teva)	University of Maryland, Baltimore	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
Brand lamotrigine	Brand lamotrigine	University of Maryland, Baltimore	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
Lamictal TM	Lamictal TM	Central Mental Clinic for Outpatients of Baku City	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant / Antiepileptic agent class)

University of Sao Paulo · 2 drugs in this class
Mario Negri Institute for Pharmacological Research · 2 drugs in this class
Janssen Korea, Ltd., Korea · 1 drug in this class
Johnson & Johnson Taiwan Ltd · 1 drug in this class
Ministry of Health and Sports, Myanmar · 1 drug in this class
Odense University Hospital · 1 drug in this class
UCB BIOSCIENCES GmbH · 1 drug in this class
University Hospitals Cleveland Medical Center · 1 drug in this class
Eisai Korea Inc. · 1 drug in this class
Upsher-Smith Laboratories · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lamotrigine novel formulation — Competitive Intelligence Brief. https://druglandscape.com/ci/lamotrigine-novel-formulation. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing